UroStream

The 2024 European Society for Medical Oncology (ESMO) Annual Meeting is being held from September 13-17 in Barcelona, Spain. Several key studies in the field of urologic cancers have attracted significant attention at the conference. Urology Frontier invited Dr. Fufu Zheng from the Department of Urology at The First Affiliated Hospital , Sun Yat-sen University to provide in-depth analysis of the major research findings presented at the conference. Professor Zheng shared his team’s latest breakthroughs in the field of urology, particularly regarding the frontier advancements in combination therapies for advanced renal cell carcinoma (RCC), while also offering insights into the promising future of RCC treatment.

Research has shown that nearly 50% of patients with muscle-invasive urothelial carcinoma (MIUC) will experience recurrence with distant metastases. Therefore, exploring perioperative treatments for muscle-invasive bladder cancer (MIBC) is crucial to improving patient outcomes. The 2024 European Society for Medical Oncology (ESMO) Congress, held from September 13 to 17 in Barcelona, Spain, highlighted several advances in perioperative immunotherapy and combination immunotherapy for MIUC patients. Dr. Wei Yu and Dr. Qi Tang from Peking University First Hospital shared their insights on this important topic.

Younger, low-risk prostate cancer patients often prioritize quality of life, particularly urinary control and sexual function, leading to ongoing clinical exploration for treatment strategies that meet these demands. From September 19 to 22, 2024, the 31st Urology Academic Conference was held at the National Convention Center in Tianjin. After the conference, Urology Frontier invited Dr. Shancheng Ren from The Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital) to discuss the advantages of extraperitoneal single-port robotic surgery, mastering surgical techniques, and the team's exploration of cutting-edge topics in urology.

Due to factors such as early screening, drug accessibility, and genetic differences, prostate cancer characteristics in China differ from those in Western countries. In recent years, with China's aging population, the incidence and mortality of prostate cancer have risen significantly, increasing the disease burden. At the recent CSCO Annual Meeting, Urology Frontier invited Dr. Yao Zhu from Fudan University Shanghai Cancer Center to share insights on the characteristics of prostate cancer in China, the latest research progress at Fudan, and the value of clinical research by physicians.

The 31st Urology Academic Conference, organized by the Chinese Medical Association and the Chinese Urological Association (CUA), was held from September 19 to 22, 2024, at the National Convention Center in Tianjin. This event brought together leading urology experts from China and abroad to discuss the latest advances in clinical research and surgical treatment. After the conference, Urology Frontier invited Dr. Jian Huang, Chair of the CUA and Director of Urology at Sun Yat-sen Memorial Hospital, Sun Yat-sen University, to share insights on the meeting's focus areas, the application of artificial intelligence (AI) in bladder cancer, and the research directions of his team.

Prostate cancer is one of the most common malignancies in men, with endocrine therapy being a standard treatment approach. However, it often comes with some side effects. Recently, the 31st Annual Urology Conference, hosted by the Chinese Medical Association and the Chinese Urological Association (CUA), was held from September 19-22, 2024, at the Tianjin National Convention Center. Following the event, Urology Frontier invited Dr. Qiang Wei from West China Hospital, Sichuan University to share insights on the latest advancements in endocrine therapy for prostate cancer, side effect management, and the future research directions of his team.

Renal cell carcinoma (RCC) is one of the most common malignancies of the urinary system. In recent years, the exploration of combined immunotherapy strategies in RCC has transformed the treatment landscape, making immuno-targeted therapy the global first-line standard for advanced renal cancer. The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain, from September 13 to 17. During the Urothelial Cancer (non-prostate) Short Oral Presentation session on September 15, Dr. Xinan Sheng from Peking University Cancer Hospital delivered a presentation titled "Anlotinib in combination with the anti-PD-L1 antibody Benmelstobart (TQB2450) versus sunitinib as first-line treatment for advanced renal cell carcinoma (RCC) - A randomized, open-label, phase III study (ETER100)." This was the only late-breaking abstract (LBA) study from China selected in the field of uro-oncology at this year's ESMO conference. Urology Frontier invited Professor Sheng to elaborate on the current state of advanced renal cancer treatment in China, the survival benefits and safety of combined immunotherapy in advanced RCC, and other key topics.

Renal cancer is one of the three major tumors of the urinary system. Several large phase III studies on combined targeted and immunotherapy have been successful, and the 2024 update of the CSCO renal cancer diagnosis and treatment guidelines has officially brought first-line treatment for advanced renal cancer into the era of combined targeted and immunotherapy in China. But what are the remaining unmet needs for patients with special types of renal cancer? During the 31st Urology Academic Conference held in Tianjin, Urology Frontier invited Dr. Hao Zeng from West China Hospital, Sichuan University to share his insights on the evolving treatment concepts for advanced renal cancer, the value of combined targeted and immunotherapy, and the West China Hospital team’s exploration into treating special types of renal cancer.

The 31st Urology Academic Conference, organized by the Chinese Medical Association and the Chinese Urological Association (CUA), took place from September 19 to 22, 2024, at the National Convention Center in Tianjin. The conference brought together leading urology experts to showcase the latest clinical research and surgical advancements. After the event, Urology Frontier invited Academician Xu Zhang, Chair-Elect of the Chinese Urological Association and Director of the Urology Department at the Chinese PLA General Hospital, to discuss conference highlights, recent advancements in PSMA-targeted radioligand therapy for prostate cancer, and the future development direction of the CUA.

Prostate cancer is one of the most common malignancies in men, and the widespread use of prostate-specific antigen (PSA) testing has significantly improved early diagnosis rates. However, a series of prostate cancer screening trials in Europe have found that PSA-based screening benefits only a subset of patients. How can more prostate cancer patients benefit from screening? Are there other biomarkers that can be used for screening? A recent article published in European Urology discusses these questions. We have summarized the key points for our readers.